# Research Idea Ranking

**Generated:** 2026-02-03T18:32:46.621749
**Model:** openai/gpt-5.2 (reasoning: high)
**Tokens:** 8713

---

### Rankings

**#1: State Medicaid Postpartum Coverage Extensions and Maternal Health (Idea 3)**
- **Score:** 74/100
- **Strengths:** High policy relevance and large-scale adoption (~38 states) create strong statistical power and timely policy value. Best in the batch on “treatment clusters” and (with the right outcomes) outcome-policy alignment.
- **Concerns:** Main risk is **outcome choice**: BRFSS is thin for postpartum-specific health, and maternal mortality in CDC WONDER is noisy with small state-year counts. Also, adoption is politically selected and may coincide with other maternal-health initiatives.
- **Novelty Assessment:** **Moderately novel.** This has been studied in recent working papers and policy reports, but the policy is new enough that there is still room for a careful, modern staggered-DiD design—especially if you contribute on outcomes and timing.
- **DiD Assessment:**
  - **Pre-treatment periods:** **Strong** (you can use long pre-periods in ACS; mortality series exist back to 1999; many states adopt 2021+).
  - **Selection into treatment:** **Marginal** (states opt in via waivers/ARPA option; likely correlated with broader health policy preferences).
  - **Comparison group:** **Marginal** (never-treated/late-treated states may differ systematically; mitigate with covariate balance checks, region trends, and event studies).
  - **Treatment clusters:** **Strong** (~38 treated states).
  - **Concurrent policies:** **Marginal** (possible overlaps: Medicaid expansion dynamics, maternal health task forces, abortion policy shifts, provider payment changes).
  - **Outcome-Policy Alignment:** **Strong if** outcomes are tightly linked (e.g., **ACS insurance coverage among women who gave birth in last 12 months**, postpartum checkup measures if available). **Weak if** relying primarily on BRFSS “general health” proxies.
  - **Data-Outcome Timing:** **Marginal** (extensions often begin mid-year; ACS measures coverage at interview date; the clean approach is to code treatment exposure based on interview month or to treat “year 1” as partial and focus on year+1 effects).
  - **Outcome Dilution:** **Marginal-to-Strong** depending on sample definition. If you use **women with a birth in the past 12 months**, the affected share is large (Medicaid-financed births ~40% nationally; extension directly targets this group). If you use all women 15–44, dilution becomes **Weak**.
- **Recommendation:** **PURSUE (conditional on: primary outcomes = ACS insurance/coverage continuity for women with birth in last 12 months; careful exposure timing using interview month or lagging treatment; do not lead with maternal mortality unless you aggregate multi-year/age-specific or use Bayesian/Poisson shrinkage and pre-specify power).**

---

**#2: State Paid Sick Leave Mandates and Influenza Mortality (Idea 5)**
- **Score:** 62/100
- **Strengths:** Novel and clearly policy-relevant externality question (contagion). Excellent long-run administrative outcome data (CDC WONDER back to 1999) supports strong pre-trend testing and flexible event-study designs.
- **Concerns:** Big threats are **outcome dilution** (flu/pneumonia deaths are concentrated among 65+) and **major confounding shocks** (COVID era, changes in testing/coding, vaccine uptake, strain severity). Annual state mortality is also noisy; you’ll need design choices to avoid attenuation.
- **Novelty Assessment:** **Fairly novel.** There is theory and some empirical work on PSL and infectious disease spread, but large-scale causal evidence on mortality specifically is not heavily saturated relative to wages/min-wage topics.
- **DiD Assessment:**
  - **Pre-treatment periods:** **Strong** (1999–2011+ gives ample pre for all adopters).
  - **Selection into treatment:** **Marginal** (PSL adoption is politically selected and correlated with other public-health policies).
  - **Comparison group:** **Marginal** (never-treated states differ; mitigate with event studies + robustness to alternative donor pools/synthetic controls).
  - **Treatment clusters:** **Strong** (≈21 treated states).
  - **Concurrent policies:** **Marginal** *if you explicitly exclude 2020–2021 and/or control for COVID intensity and other NPIs;* otherwise **Weak** because 2020+ overwhelms flu dynamics.
  - **Outcome-Policy Alignment:** **Marginal** (PSL plausibly reduces workplace transmission, but mortality is downstream and mediated by many factors; alignment improves if you focus on **working-age (18–64) influenza/pneumonia mortality** rather than all-age).
  - **Data-Outcome Timing:** **Marginal** (WONDER annual deaths are calendar-year; many PSL laws effective Jan 1 or mid-year—partial exposure in adoption year. A clean fix is to drop/flag the first partial year or use monthly mortality if feasible.)
  - **Outcome Dilution:** **Weak as stated** if using all-age influenza/pneumonia mortality (working-age share of these deaths is often <10–20% ⇒ PSL’s “treated” population is a small fraction of deaths). Becomes **Marginal** if you restrict to 18–64 and/or high-exposure occupations.
- **Recommendation:** **CONSIDER (conditional on: age-restricted outcomes, ideally 18–64; exclude or separately model 2020–2021; treat adoption year as partial exposure; incorporate controls for flu severity/vaccine uptake proxies and test sensitivity to excluding severe flu seasons).**

---

**#3: Paid Sick Leave Mandates and Preventive Healthcare Utilization (Idea 1)**
- **Score:** 45/100
- **Strengths:** Interesting welfare channel (time flexibility) and BRFSS offers broad population coverage and subgroup cuts that claims data miss. Staggered adoption with a decent number of treated states is attractive in principle.
- **Concerns:** As proposed, it likely fails on **timing** (BRFSS “past 12 months” measures + within-year surveying) and **dilution** (many outcomes—especially flu shots 65+—are dominated by people not directly affected by worker PSL mandates). Also, earliest adopter (CT 2012) plus data starting 2011 gives essentially no pre-period for that state.
- **Novelty Assessment:** **Moderately novel but adjacent to existing PSL-health literature.** Preventive care specifically is less saturated than labor-market outcomes, but “PSL → health utilization” is not virgin territory.
- **DiD Assessment:**
  - **Pre-treatment periods:** **Weak** *as written* (data 2011–2024 with CT treated in 2012 ⇒ ≤1 pre-year for earliest treated; this is a dealbreaker unless you extend BRFSS earlier or drop early adopters).
  - **Selection into treatment:** **Marginal** (policy adoption correlated with progressive policy bundles and underlying health systems).
  - **Comparison group:** **Marginal** (never-treated states likely differ; triple-diff helps but doesn’t fully solve).
  - **Treatment clusters:** **Strong** (≈21+ treated states).
  - **Concurrent policies:** **Marginal-to-Weak** (PSL often coincides with minimum wage hikes, Medicaid changes, public health campaigns).
  - **Outcome-Policy Alignment:** **Marginal** (PSL could affect ability to attend appointments; but “routine checkup” and “dental visit” are influenced by insurance/provider access more than short-term leave availability).
  - **Data-Outcome Timing:** **Weak** (BRFSS preventive care is typically “within past 12 months” and interviews occur throughout the year; adoption-year outcomes mechanically include substantial pre-treatment recall unless you lag treatment/exposure).
  - **Outcome Dilution:** **Weak** for several proposed outcomes. Example: **flu vaccination (65+)** is mostly retired (likely <5–10% directly affected by worker PSL). Even “all adults” measures include many non-covered or non-working individuals; affected share plausibly ~15–30% depending on subgroup.
- **Recommendation:** **SKIP (unless redesigned).** To revive: (i) extend pre-period or drop earliest adopters until you have ≥5 pre-years; (ii) focus on working-age employed populations and outcomes with closer alignment; (iii) lag treatment by 1 year (or use interview-month exposure).

---

**#4: State E-Cigarette Indoor Air Laws and Youth Vaping Prevalence (Idea 2)**
- **Score:** 38/100
- **Strengths:** Potentially high novelty relative to taxes/flavor bans, and youth vaping is a clear policy priority. Outcome-policy alignment is conceptually good if the law affects use contexts and normalization.
- **Concerns:** **Data feasibility and identification are major risks**: YRBSS is biennial and not consistently state-representative across all states/years; BRFSS is adults (mismatch for “youth vaping”). Pre-treatment periods are likely too short because consistent vaping questions begin relatively late, while laws start earlier; concurrent tobacco policies are rampant.
- **Novelty Assessment:** **Fairly novel** (indoor-use restrictions are less studied than taxes), but novelty doesn’t compensate for weak identification/data.
- **DiD Assessment:**
  - **Pre-treatment periods:** **Weak** (vaping measures largely appear ~2015/2016+; many adoptions occur soon after ⇒ ≤2 pre-periods for many states).
  - **Selection into treatment:** **Weak** (states likely adopt in response to rising youth vaping—selection on trends is very plausible).
  - **Comparison group:** **Marginal** (never-treated states may be systematically different; could partially mitigate with matched comparisons).
  - **Treatment clusters:** **Marginal** (~20 states; acceptable, but effective sample shrinks with YRBSS participation).
  - **Concurrent policies:** **Weak** (Tobacco21 laws, e-cig taxes, flavor bans, retail licensing, enforcement changes—often contemporaneous).
  - **Outcome-Policy Alignment:** **Strong** *if* you use youth vaping prevalence; **Weak** if you end up using adult BRFSS vaping as a substitute.
  - **Data-Outcome Timing:** **Marginal-to-Weak** (YRBSS fielded mostly spring; if laws effective mid-year or late-year, the “treated year” may be pre-exposure).
  - **Outcome Dilution:** **Strong** (policy targets the same population you would measure—youth—*if* data are available and representative).
- **Recommendation:** **SKIP** unless you can (i) assemble a consistent state-year youth vaping panel with enough pre-years, (ii) credibly isolate from other tobacco policies (or study a cleaner policy shock), and (iii) align treatment to survey month.

---

**#5: State Minimum Wage Increases and Preventive Healthcare Utilization (Idea 4)**
- **Score:** 32/100
- **Strengths:** Data are feasible and variation is abundant; question is policy-relevant in broad terms. Easy to implement empirically.
- **Concerns:** Identification is the weakest in the set because minimum wage changes are deeply entangled with **state political economy trends and concurrent policy bundles** (health expansions, labor regs, local economic cycles). Preventive care measures in BRFSS also suffer from recall/timing problems and strong dilution unless you can isolate low-wage workers precisely.
- **Novelty Assessment:** **Low-to-moderate novelty.** Minimum wage effects (including on health and health behaviors) have a large literature; “preventive care” is a narrower angle, but not enough to offset identification concerns.
- **DiD Assessment:**
  - **Pre-treatment periods:** **Marginal** (you *can* get long pre-trends historically, but the proposal ties to the same BRFSS preventive series—often used from 2011+—and different outcomes/questions change over time).
  - **Selection into treatment:** **Marginal** (not random; strongly correlated with ideology and macro trends; less clearly driven by preventive care trends, but still endogenous).
  - **Comparison group:** **Marginal** (control states differ structurally; spillovers across borders/local laws complicate).
  - **Treatment clusters:** **Strong** (many state-year policy changes).
  - **Concurrent policies:** **Weak** (progressive policy bundling is pervasive; hard to argue minimum wage is the marginal change affecting preventive care).
  - **Outcome-Policy Alignment:** **Marginal** (income channel plausible, but preventive care is mediated heavily by insurance/provider access and public programs).
  - **Data-Outcome Timing:** **Weak** (BRFSS “past 12 months” + within-year interviews; mid-year wage changes create partial exposure and recall contamination).
  - **Outcome Dilution:** **Weak** (minimum wage directly affects a minority of adults—often ~10–20%; preventive care measured on broad populations).
- **Recommendation:** **SKIP.**

---

### Summary

This batch has one clearly fundable direction: **postpartum Medicaid extensions (Idea 3)**, provided outcomes and exposure timing are defined tightly to avoid dilution and partial-year bias. **PSL and influenza mortality (Idea 5)** is the most interesting “big idea,” but it needs redesign around age-specific outcomes and pandemic-era confounding. The remaining BRFSS preventive-care ideas (Ideas 1 and 4) are undermined by **timing/recall mismatch and dilution**, while the youth vaping DiD (Idea 2) is primarily a **data + selection-on-trends** problem.